A Peek at Harmony Biosciences's Future Earnings

Harmony Biosciences (NASDAQ:HRMY) is gearing up to announce its quarterly earnings on Tuesday, 2026-02-24. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Harmony Biosciences will report an earnings per share (EPS) of $0.98.

Harmony Biosciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

The company's EPS beat by $0.20 in the last quarter, leading to a 2.05% increase in the share price on the following day.

Here's a look at Harmony Biosciences's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	0.88	0.89	0.91	0.82
EPS Actual	1.08	0.92	1.03	1.08
Price Change %	2.00	-1.00	4.00	-9.00

Tracking Harmony Biosciences's Stock Performance

Shares of Harmony Biosciences were trading at $29.16 as of February 20. Over the last 52-week period, shares are down 27.1%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Analyst Opinions on Harmony Biosciences

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Harmony Biosciences.

The consensus rating for Harmony Biosciences is , based on analyst ratings. With an average one-year price target of $, there's a potential .

To track all earnings releases for Harmony Biosciences visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.